Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00189917|
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : June 3, 2015
|Condition or disease||Intervention/treatment||Phase|
|Dermatitis, Atopic Hay Fever||Biological: IMVAMUNE (MVA-BN)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders|
|Study Start Date :||April 2004|
|Study Completion Date :||April 2006|
- Occurrence, relationship and intensity of any serious adverse event at any time during the study.
- ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points).
- Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189917
|Department of Infectious Diseases and Tropical Medicine|
|Munich, Bavaria, Germany, 80802|
|Principal Investigator:||Frank von Sonnenburg, M.D.||Department of Infectious Diseases and Tropical Medicine of the University of Munich|